Next Generation Treatments

Next Generation TreatmentsThe next generation of hepatitis C treatments is coming. This webpage summarizes these possible hep C treatments, treatments that are currently within the early stages of clinical trials. These treatments may or may not be successfully approved for use and, if they are approved, may take a number of years to do so.

If you are looking for information about hep C treatments further along in the drug approval process, please check out our Hep C Drug Pipeline Treatments page. But, if you are looking for information about currently approved hep C treatments, look for their pages in the drop-down menu under BC’s PharmaCare Covered Treatments or check out our Treatment Coverage Across Canada page.

Treatments in the Early Stages of Clinical Trials

Pharmaceutical Companies Treatments Currently Targeted Genotypes
AbbVie ABT-493 / ABT-530 1-6
Enanta EDP-494 1,3
Gilead Sofosbuvir / Velpatasvir + GS-9857* 1-6
Janssen AL-335 + Odalasvir (ACHN-3102) + Simeprevir 1-6
Merck Grazoprevir (MK-5172) and MK-3682 with Elbasvir (MK-8742) or MK-8408 3-6
Regulus RG-101 All
*GS-9857’s generic name is voxilaprevir.

Maker: AbbVie

Treatment: ABT-493 / ABT-530

Targeted Genotype: 1-6

Treatment Description: ABT-493 / ABT-530 is made up of 2 direct-acting antivirals, ABT-493, a NS3/4A protease inhibitor, and ABT-530, a NS5A inhibitor, This treatment is achieving good clinical trial results without having to be combined with ribavirin.

  • ABT-493 / ABT-530

Approximate Sustained Viral Response (SVR)/”Cure Rate”: 100%

Possible Daily Dose: 1 pill

Possible Length of Treatment: 8 or 12 weeks

Common Side Effects Reported in Clinical Trials:

  • Diarrhea
  • Headache
  • Tiredness (fatigue)

Steps in Drug Approval Pipeline: Step 1 – Testing

Additional Information:

Maker: Enanta

Treatment: EDP-494

Targeted Genotypes: 1, 3

Treatment Description: EDP-494, a Cyclophilin Inhibitor, targets a patient’s cyclophilin, a protein that is essential for replication of the hep C virus. As it targets different virus elements, it is hoped that it will cure patients resistant to direct-acting antiviral hep C therapies. The plan is to combine it with a DAA.

  • EDP-494 +
  • DAA

Steps in Drug Approval Pipeline: Step 1 – Testing

Additional Information:

  • Enanta Pharmaceuticals Initiates Proof-of-Concept Study with Pan-genotypic Cyclophilin Inhibitor EDP-494 in Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Virus

Maker: Gilead

Treatment: Sofosbuvir / Velpatasvir / GS-9857

Targeted Genotypes: 1 – 6

Treatment Description: Sofosbuvir / Velpatasvir / GS-9857 is made up of 3 direct-acting antivirals. GS-9857’s generic name is voxilaprevir.

  • Sovaldi +
  • Velpatasvir +
  • GS-9857 (Voxilaprevir)

Approximate Sustained Viral Response (SVR)/”Cure Rate”85 – 100% depending on the virus’ genotype and the patient’s health

Possible Daily Dose: 1 pill

Possible Length of Treatment:  6 – 12 weeks

Common Side Effects Reported in Clinical Trials:

  • Diarrhea
  • Headache
  • Nausea
  • Tiredness (fatigue)

Steps in Drug Approval Pipeline: Step 1 – Testing

Additional Information:

  • Sofosbuvir/velpatasvir + GS-9857 for 8 weeks cures hepatitis C for most people with genotype 1 or 3
  • Sofosbuvir/velpatasvir + GS-9857 works well for treatment-experienced hepatitis C patients

Maker: Janssen

Treatment: AL-335 + Odalasvir (ACHN-3102) + Simeprevir

Targeted Genotype: 1-6

Treatment Description: AL-335 is a nucleotide polymerase inhibitor and odalasvir (ACHN-3102) is a NS5A inhibitor. Simeprevir (brand name Galexos) is a NS3/4A protease inhibitors. These inhibitors work by blocking viral enzymes (protease) that enables the hep C virus to survive and replicate in host cells.

  • AL-335 +
  • Odalasvir (ACHN-3102) +
  • Simeprevir (brand name Galexos)

Possible Daily Dose: 1 pill

Step in Drug Approval Pipeline: Step 1 – Testing

Additional Information:

  • Janssen to Unveil New Hepatitis B and C Data at The International Liver Congress™ 2016 of the European Association for the Study of the Liver (EASL)

Maker: Merck

Treatment: Grazoprevir (MK-5172) and MK-3682 with Elbasvir (MK-8742) or MK-8408

Possible Targeted Genotypes: 3-6

Potential Combinations:

  • Grazoprevir (MK-5172) + MK-3682 +/-
  • Elbasvir (MK-8742) or MK-8408 +/-
  • Ribavirin

Possible Length of Treatment: 8 – 24 weeks

Possible Daily Dose: 2 pills once daily

Step in Drug Approval Pipeline: Step 1 – Testing

Additional Information:

  • Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 with Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)

Maker: Regulus

Treatment: RG-101

Targeted Genotypes: All

Treatment Description: RG-101 works with direct-acting antivirals to reduce viral load counts and lessen required treatment lengths.

Possible Length of Treatment: 4 – 12 weeks

Common Side Effects Reported in Clinical Trials:

  • Headache
  • Jaundice
  • Tiredness (fatigue)

Step in Drug Approval Pipeline: Step 1 – Testing, Clinical trial hold (see below for more information)

Additional Information:

  • Shorter treatment course potentially on the horizon for Hepatitis C patients
  • RG-101 written by Regulus
  • Regulus Reports FDA Clinical Hold of RG-101, June 27th, 2016

The information on this website is meant as a resource only and is not intended to replace qualified medical attention. Please seek advise and guidance from your health practitioners when considering your hep C treatment options.

BPD